| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Incontinence, Stress | 34 | 2022 | 60 | 10.600 |
Why?
|
| Urinary Bladder, Overactive | 32 | 2022 | 41 | 8.200 |
Why?
|
| Suburethral Slings | 19 | 2021 | 35 | 7.750 |
Why?
|
| Urinary Incontinence | 32 | 2022 | 67 | 5.600 |
Why?
|
| Urologic Surgical Procedures | 19 | 2021 | 47 | 5.030 |
Why?
|
| Muscarinic Antagonists | 23 | 2021 | 54 | 3.840 |
Why?
|
| Urinary Bladder | 27 | 2020 | 108 | 3.800 |
Why?
|
| Surgical Mesh | 10 | 2020 | 57 | 3.710 |
Why?
|
| Urodynamics | 18 | 2021 | 43 | 3.350 |
Why?
|
| Urethral Diseases | 9 | 2020 | 21 | 3.260 |
Why?
|
| Diverticulum | 8 | 2020 | 29 | 3.130 |
Why?
|
| Urinary Incontinence, Urge | 9 | 2022 | 12 | 2.630 |
Why?
|
| Pelvic Organ Prolapse | 5 | 2020 | 50 | 2.190 |
Why?
|
| Botulinum Toxins, Type A | 7 | 2018 | 31 | 2.170 |
Why?
|
| Urinary Bladder, Neurogenic | 6 | 2021 | 11 | 2.060 |
Why?
|
| Vagina | 9 | 2020 | 87 | 2.000 |
Why?
|
| Postoperative Complications | 11 | 2021 | 1615 | 1.960 |
Why?
|
| Phenylpropanolamine | 12 | 2009 | 16 | 1.830 |
Why?
|
| Urological Agents | 5 | 2021 | 7 | 1.820 |
Why?
|
| Urethra | 13 | 2022 | 56 | 1.770 |
Why?
|
| Urinary Bladder Diseases | 9 | 2014 | 26 | 1.740 |
Why?
|
| Female | 118 | 2022 | 38015 | 1.710 |
Why?
|
| Urinary Retention | 3 | 2020 | 20 | 1.680 |
Why?
|
| Device Removal | 4 | 2017 | 100 | 1.640 |
Why?
|
| Benzhydryl Compounds | 14 | 2009 | 62 | 1.610 |
Why?
|
| Humans | 156 | 2022 | 68525 | 1.600 |
Why?
|
| Polypropylenes | 5 | 2020 | 31 | 1.590 |
Why?
|
| Prosthesis Implantation | 3 | 2021 | 83 | 1.570 |
Why?
|
| Treatment Outcome | 43 | 2022 | 7028 | 1.560 |
Why?
|
| Cresols | 12 | 2009 | 17 | 1.490 |
Why?
|
| Middle Aged | 82 | 2021 | 21119 | 1.470 |
Why?
|
| Cystitis, Interstitial | 9 | 2017 | 12 | 1.450 |
Why?
|
| Lower Urinary Tract Symptoms | 6 | 2021 | 13 | 1.360 |
Why?
|
| Aged | 66 | 2021 | 14842 | 1.360 |
Why?
|
| Quality of Life | 17 | 2022 | 1515 | 1.320 |
Why?
|
| Reoperation | 8 | 2021 | 467 | 1.260 |
Why?
|
| Muscle, Smooth | 11 | 2020 | 117 | 1.230 |
Why?
|
| Gynecologic Surgical Procedures | 5 | 2016 | 37 | 1.210 |
Why?
|
| Neuromuscular Agents | 4 | 2015 | 22 | 1.200 |
Why?
|
| Urinary Catheterization | 7 | 2015 | 27 | 1.190 |
Why?
|
| Tolterodine Tartrate | 13 | 2017 | 17 | 1.130 |
Why?
|
| Surgical Flaps | 3 | 2019 | 120 | 1.060 |
Why?
|
| Cystoscopy | 10 | 2020 | 23 | 1.050 |
Why?
|
| Muscle Contraction | 12 | 2020 | 210 | 1.040 |
Why?
|
| Adult | 57 | 2021 | 21375 | 0.990 |
Why?
|
| Urinary Bladder Neck Obstruction | 4 | 2021 | 12 | 0.970 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channels | 8 | 2017 | 17 | 0.960 |
Why?
|
| Tibial Nerve | 4 | 2019 | 10 | 0.950 |
Why?
|
| Dysuria | 2 | 2020 | 3 | 0.920 |
Why?
|
| Denervation | 2 | 2019 | 23 | 0.890 |
Why?
|
| Urination Disorders | 8 | 2006 | 20 | 0.890 |
Why?
|
| Acetanilides | 3 | 2021 | 9 | 0.880 |
Why?
|
| Urology | 6 | 2021 | 31 | 0.870 |
Why?
|
| Thiazoles | 3 | 2021 | 95 | 0.840 |
Why?
|
| Retrospective Studies | 21 | 2021 | 7264 | 0.840 |
Why?
|
| Uterine Prolapse | 5 | 2007 | 29 | 0.830 |
Why?
|
| Electric Stimulation Therapy | 4 | 2019 | 147 | 0.800 |
Why?
|
| Nortropanes | 5 | 2011 | 5 | 0.790 |
Why?
|
| Bulbourethral Glands | 1 | 2020 | 1 | 0.780 |
Why?
|
| United States Food and Drug Administration | 3 | 2016 | 131 | 0.720 |
Why?
|
| Dyspnea | 1 | 2020 | 87 | 0.710 |
Why?
|
| Urinary Fistula | 1 | 2019 | 7 | 0.700 |
Why?
|
| Male | 65 | 2020 | 37281 | 0.690 |
Why?
|
| Electrodes, Implanted | 1 | 2019 | 98 | 0.670 |
Why?
|
| Balloon Occlusion | 2 | 2018 | 22 | 0.660 |
Why?
|
| Adrenergic beta-3 Receptor Agonists | 2 | 2015 | 3 | 0.660 |
Why?
|
| Follow-Up Studies | 15 | 2019 | 3256 | 0.640 |
Why?
|
| Genetic Therapy | 1 | 2020 | 291 | 0.630 |
Why?
|
| Prospective Studies | 13 | 2022 | 3702 | 0.630 |
Why?
|
| Antidiuretic Agents | 1 | 2017 | 1 | 0.620 |
Why?
|
| Nocturia | 1 | 2017 | 3 | 0.620 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2017 | 15 | 0.610 |
Why?
|
| Ureter | 1 | 2017 | 16 | 0.610 |
Why?
|
| Electric Stimulation | 5 | 2015 | 218 | 0.610 |
Why?
|
| Disease Management | 1 | 2019 | 248 | 0.600 |
Why?
|
| Dimethyl Sulfoxide | 1 | 2017 | 30 | 0.600 |
Why?
|
| Myiasis | 1 | 2016 | 1 | 0.580 |
Why?
|
| Aged, 80 and over | 23 | 2021 | 4843 | 0.560 |
Why?
|
| Myocytes, Smooth Muscle | 8 | 2017 | 144 | 0.560 |
Why?
|
| Analgesics | 1 | 2017 | 118 | 0.540 |
Why?
|
| Biocompatible Materials | 4 | 2010 | 247 | 0.530 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2015 | 24 | 0.520 |
Why?
|
| Prosthesis Failure | 2 | 2016 | 130 | 0.520 |
Why?
|
| Public Opinion | 1 | 2014 | 32 | 0.500 |
Why?
|
| Physical Therapy Modalities | 1 | 2015 | 133 | 0.480 |
Why?
|
| Consumer Product Safety | 1 | 2014 | 32 | 0.480 |
Why?
|
| Delayed-Action Preparations | 9 | 2010 | 120 | 0.480 |
Why?
|
| Double-Blind Method | 10 | 2020 | 1737 | 0.470 |
Why?
|
| Prostatectomy | 3 | 2011 | 87 | 0.470 |
Why?
|
| Kidney Diseases | 1 | 2016 | 307 | 0.460 |
Why?
|
| Pain | 1 | 2017 | 472 | 0.460 |
Why?
|
| Adrenergic alpha-Antagonists | 3 | 2021 | 32 | 0.460 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 4 | 2020 | 6 | 0.450 |
Why?
|
| Prostatic Hyperplasia | 3 | 2008 | 25 | 0.440 |
Why?
|
| Recurrence | 5 | 2016 | 948 | 0.430 |
Why?
|
| Multiple Sclerosis | 2 | 2015 | 132 | 0.430 |
Why?
|
| Prostheses and Implants | 1 | 2013 | 159 | 0.420 |
Why?
|
| Urinary Tract | 2 | 2021 | 10 | 0.420 |
Why?
|
| Sulfonamides | 3 | 2016 | 141 | 0.400 |
Why?
|
| Administration, Intravesical | 3 | 2020 | 8 | 0.400 |
Why?
|
| Urologic Diseases | 3 | 2016 | 11 | 0.390 |
Why?
|
| Urogenital Surgical Procedures | 2 | 2006 | 4 | 0.360 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2017 | 2222 | 0.360 |
Why?
|
| Receptors, Muscarinic | 2 | 2014 | 44 | 0.360 |
Why?
|
| Suture Techniques | 3 | 1999 | 75 | 0.360 |
Why?
|
| United States | 11 | 2021 | 7335 | 0.350 |
Why?
|
| Surveys and Questionnaires | 8 | 2019 | 2798 | 0.340 |
Why?
|
| Vaginal Diseases | 2 | 2006 | 11 | 0.340 |
Why?
|
| Single-Blind Method | 4 | 2018 | 249 | 0.340 |
Why?
|
| Risk Assessment | 5 | 2021 | 2004 | 0.340 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 766 | 0.330 |
Why?
|
| Prostatic Neoplasms | 5 | 2004 | 778 | 0.320 |
Why?
|
| Spinal Dysraphism | 1 | 2007 | 8 | 0.310 |
Why?
|
| Sexuality | 1 | 2007 | 12 | 0.310 |
Why?
|
| Intraoperative Complications | 2 | 2007 | 129 | 0.310 |
Why?
|
| Severity of Illness Index | 4 | 2017 | 1851 | 0.310 |
Why?
|
| Spinal Cord Injuries | 2 | 2015 | 551 | 0.300 |
Why?
|
| Registries | 3 | 2021 | 730 | 0.300 |
Why?
|
| Dyspareunia | 2 | 2017 | 7 | 0.300 |
Why?
|
| Membrane Potentials | 8 | 2016 | 200 | 0.300 |
Why?
|
| TRPM Cation Channels | 2 | 2017 | 5 | 0.300 |
Why?
|
| Hematuria | 3 | 2001 | 24 | 0.290 |
Why?
|
| Fascia | 2 | 2016 | 17 | 0.290 |
Why?
|
| Urethral Stricture | 1 | 2006 | 19 | 0.290 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2016 | 1745 | 0.280 |
Why?
|
| Guideline Adherence | 1 | 2008 | 284 | 0.270 |
Why?
|
| Drug Therapy | 2 | 2002 | 71 | 0.250 |
Why?
|
| Public Health | 2 | 2016 | 201 | 0.240 |
Why?
|
| Parasympatholytics | 1 | 2004 | 19 | 0.240 |
Why?
|
| Benzilates | 5 | 2011 | 6 | 0.240 |
Why?
|
| Injections, Intramuscular | 2 | 2016 | 44 | 0.240 |
Why?
|
| Radiation Injuries | 1 | 2004 | 97 | 0.240 |
Why?
|
| Research Design | 3 | 2018 | 729 | 0.240 |
Why?
|
| Urinary Diversion | 3 | 2015 | 16 | 0.230 |
Why?
|
| Laparoscopy | 2 | 2010 | 237 | 0.230 |
Why?
|
| Equipment Design | 2 | 2017 | 500 | 0.230 |
Why?
|
| Dermis | 1 | 2003 | 29 | 0.220 |
Why?
|
| Small-Conductance Calcium-Activated Potassium Channels | 2 | 2012 | 27 | 0.220 |
Why?
|
| Time Factors | 5 | 2017 | 4655 | 0.220 |
Why?
|
| Urinary Tract Infections | 2 | 2017 | 71 | 0.210 |
Why?
|
| Endoscopy | 1 | 2005 | 464 | 0.200 |
Why?
|
| Drug Combinations | 2 | 2017 | 304 | 0.200 |
Why?
|
| Patient Selection | 3 | 2014 | 592 | 0.200 |
Why?
|
| Estrogens | 2 | 2017 | 173 | 0.200 |
Why?
|
| Urinary Bladder Fistula | 1 | 2001 | 9 | 0.200 |
Why?
|
| Patch-Clamp Techniques | 7 | 2016 | 204 | 0.200 |
Why?
|
| Fistula | 1 | 2001 | 29 | 0.200 |
Why?
|
| Muscular Diseases | 1 | 2001 | 41 | 0.190 |
Why?
|
| Dilatation, Pathologic | 1 | 2020 | 58 | 0.190 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 2 | 1997 | 6 | 0.190 |
Why?
|
| Aftercare | 1 | 2021 | 114 | 0.190 |
Why?
|
| Intermittent Urethral Catheterization | 2 | 2021 | 2 | 0.190 |
Why?
|
| Angiomyolipoma | 1 | 2000 | 4 | 0.190 |
Why?
|
| Feasibility Studies | 2 | 2019 | 652 | 0.180 |
Why?
|
| Phenanthrenes | 1 | 2020 | 18 | 0.180 |
Why?
|
| Cations | 1 | 2020 | 51 | 0.180 |
Why?
|
| Leydig Cell Tumor | 1 | 1999 | 1 | 0.180 |
Why?
|
| Cohort Studies | 3 | 2014 | 2356 | 0.180 |
Why?
|
| Hernia, Ventral | 1 | 2000 | 35 | 0.180 |
Why?
|
| Testicular Neoplasms | 1 | 1999 | 27 | 0.180 |
Why?
|
| Nickel | 1 | 2019 | 18 | 0.170 |
Why?
|
| Mandelic Acids | 3 | 2004 | 4 | 0.170 |
Why?
|
| Polyethylenes | 1 | 1999 | 31 | 0.170 |
Why?
|
| Xanthines | 2 | 2016 | 17 | 0.170 |
Why?
|
| Catheters, Indwelling | 2 | 2011 | 72 | 0.170 |
Why?
|
| Administration, Oral | 3 | 2006 | 411 | 0.170 |
Why?
|
| Leeches | 1 | 1998 | 2 | 0.160 |
Why?
|
| Action Potentials | 3 | 2017 | 223 | 0.160 |
Why?
|
| Kidney Neoplasms | 1 | 2000 | 206 | 0.160 |
Why?
|
| Endpoint Determination | 1 | 2018 | 82 | 0.160 |
Why?
|
| Collagen | 4 | 2010 | 636 | 0.160 |
Why?
|
| Self Care | 2 | 2014 | 252 | 0.160 |
Why?
|
| Treatment Failure | 2 | 2014 | 216 | 0.160 |
Why?
|
| Transplantation, Autologous | 2 | 2016 | 145 | 0.160 |
Why?
|
| Patient Safety | 1 | 2020 | 202 | 0.160 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 1 | 2017 | 13 | 0.150 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 2017 | 40 | 0.150 |
Why?
|
| Urine | 1 | 2017 | 47 | 0.150 |
Why?
|
| Proof of Concept Study | 1 | 2017 | 38 | 0.150 |
Why?
|
| Societies, Medical | 3 | 2021 | 403 | 0.150 |
Why?
|
| DNA | 1 | 2020 | 597 | 0.150 |
Why?
|
| Prognosis | 3 | 2014 | 2093 | 0.150 |
Why?
|
| Acetylcholine Release Inhibitors | 1 | 2016 | 2 | 0.140 |
Why?
|
| Potassium Channel Blockers | 5 | 2014 | 32 | 0.140 |
Why?
|
| Prostate-Specific Antigen | 1 | 1997 | 138 | 0.140 |
Why?
|
| Ivermectin | 1 | 2016 | 12 | 0.140 |
Why?
|
| Antiparasitic Agents | 1 | 2016 | 12 | 0.140 |
Why?
|
| Precision Medicine | 1 | 2017 | 111 | 0.140 |
Why?
|
| Phosphodiesterase I | 1 | 2016 | 3 | 0.140 |
Why?
|
| Estradiol | 1 | 2017 | 176 | 0.140 |
Why?
|
| Gynecology | 1 | 2016 | 46 | 0.140 |
Why?
|
| Clinical Competence | 1 | 2021 | 657 | 0.140 |
Why?
|
| Symptom Assessment | 1 | 2016 | 33 | 0.140 |
Why?
|
| Patient Satisfaction | 3 | 2010 | 378 | 0.140 |
Why?
|
| Tissue Engineering | 2 | 2015 | 212 | 0.140 |
Why?
|
| Lumbosacral Plexus | 1 | 2015 | 15 | 0.130 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 2 | 2014 | 56 | 0.130 |
Why?
|
| Peptides | 6 | 2014 | 455 | 0.130 |
Why?
|
| Reproducibility of Results | 3 | 2014 | 2077 | 0.130 |
Why?
|
| Referral and Consultation | 3 | 2018 | 383 | 0.130 |
Why?
|
| Behavior Therapy | 3 | 2012 | 297 | 0.130 |
Why?
|
| Biopsy, Needle | 3 | 2008 | 191 | 0.130 |
Why?
|
| Anastomosis, Surgical | 1 | 2014 | 104 | 0.130 |
Why?
|
| Penile Erection | 2 | 2007 | 18 | 0.130 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 281 | 0.120 |
Why?
|
| Statistics, Nonparametric | 1 | 2014 | 306 | 0.120 |
Why?
|
| Placebos | 3 | 2011 | 195 | 0.120 |
Why?
|
| Electromyography | 1 | 2014 | 184 | 0.120 |
Why?
|
| Dilatation | 2 | 2006 | 58 | 0.120 |
Why?
|
| Ethanolamines | 1 | 2013 | 33 | 0.120 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 951 | 0.120 |
Why?
|
| Artifacts | 1 | 2014 | 125 | 0.120 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 103 | 0.110 |
Why?
|
| Cells, Cultured | 6 | 2017 | 2673 | 0.110 |
Why?
|
| Primary Health Care | 1 | 1999 | 702 | 0.110 |
Why?
|
| Fluoroscopy | 1 | 2014 | 152 | 0.110 |
Why?
|
| Benzothiazoles | 1 | 2012 | 14 | 0.110 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 1 | 1 | 2012 | 1 | 0.110 |
Why?
|
| Radiography | 3 | 2004 | 572 | 0.110 |
Why?
|
| Pressure | 1 | 2013 | 252 | 0.110 |
Why?
|
| Gene Expression Regulation | 3 | 2013 | 1293 | 0.110 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2012 | 22 | 0.110 |
Why?
|
| Intermediate-Conductance Calcium-Activated Potassium Channels | 1 | 2012 | 4 | 0.110 |
Why?
|
| Shab Potassium Channels | 1 | 2012 | 6 | 0.110 |
Why?
|
| Calcium Channels | 1 | 2012 | 59 | 0.110 |
Why?
|
| Kidney | 1 | 2017 | 945 | 0.110 |
Why?
|
| Prosthesis Design | 1 | 2013 | 301 | 0.100 |
Why?
|
| Prevalence | 1 | 2016 | 1609 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 424 | 0.100 |
Why?
|
| Intention to Treat Analysis | 1 | 2011 | 38 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 503 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2006 | 929 | 0.100 |
Why?
|
| Video Recording | 1 | 2011 | 145 | 0.100 |
Why?
|
| Carbachol | 3 | 2016 | 34 | 0.090 |
Why?
|
| Robotics | 1 | 2010 | 56 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2010 | 772 | 0.090 |
Why?
|
| Cholinergic Antagonists | 2 | 2012 | 17 | 0.090 |
Why?
|
| Dextrans | 1 | 2009 | 33 | 0.090 |
Why?
|
| Cadaver | 2 | 2016 | 136 | 0.090 |
Why?
|
| Patient Compliance | 2 | 2018 | 402 | 0.090 |
Why?
|
| Drug Therapy, Combination | 2 | 2008 | 648 | 0.090 |
Why?
|
| Biomarkers | 4 | 2008 | 1593 | 0.090 |
Why?
|
| Pelvic Floor | 2 | 2000 | 21 | 0.090 |
Why?
|
| Drug Administration Schedule | 3 | 2011 | 567 | 0.090 |
Why?
|
| In Vitro Techniques | 3 | 2016 | 765 | 0.080 |
Why?
|
| American Civil War | 1 | 2008 | 3 | 0.080 |
Why?
|
| Urination | 1 | 2008 | 19 | 0.080 |
Why?
|
| Ulcer | 1 | 2008 | 27 | 0.080 |
Why?
|
| Cystitis | 2 | 2005 | 18 | 0.080 |
Why?
|
| Hyaluronic Acid | 1 | 2009 | 206 | 0.080 |
Why?
|
| Tissue Culture Techniques | 3 | 2012 | 62 | 0.080 |
Why?
|
| Sildenafil Citrate | 1 | 2007 | 23 | 0.080 |
Why?
|
| Sex Education | 1 | 2007 | 20 | 0.080 |
Why?
|
| Infertility, Male | 1 | 2007 | 35 | 0.080 |
Why?
|
| Purines | 1 | 2007 | 39 | 0.080 |
Why?
|
| Sulfones | 1 | 2007 | 45 | 0.080 |
Why?
|
| Insufflation | 1 | 2007 | 4 | 0.080 |
Why?
|
| Schools, Medical | 1 | 2008 | 157 | 0.070 |
Why?
|
| Choristoma | 1 | 2007 | 20 | 0.070 |
Why?
|
| Rare Diseases | 1 | 2007 | 41 | 0.070 |
Why?
|
| Cervix Uteri | 1 | 2007 | 64 | 0.070 |
Why?
|
| Receptor, Muscarinic M3 | 1 | 2006 | 10 | 0.070 |
Why?
|
| Receptor, Muscarinic M2 | 1 | 2006 | 8 | 0.070 |
Why?
|
| Cysts | 1 | 2007 | 70 | 0.070 |
Why?
|
| Medication Adherence | 1 | 2009 | 335 | 0.070 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2019 | 114 | 0.070 |
Why?
|
| Europe | 1 | 2006 | 195 | 0.070 |
Why?
|
| Piperazines | 1 | 2007 | 206 | 0.070 |
Why?
|
| Epidemiologic Methods | 3 | 2010 | 83 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2008 | 1039 | 0.070 |
Why?
|
| Vesicovaginal Fistula | 1 | 2005 | 2 | 0.070 |
Why?
|
| Vaginal Discharge | 1 | 2005 | 3 | 0.070 |
Why?
|
| Sex Factors | 1 | 2009 | 1265 | 0.070 |
Why?
|
| Vaginitis | 1 | 2005 | 21 | 0.070 |
Why?
|
| Methylhistamines | 1 | 2004 | 1 | 0.070 |
Why?
|
| Calcium | 3 | 2014 | 929 | 0.060 |
Why?
|
| Biofeedback, Psychology | 1 | 2004 | 23 | 0.060 |
Why?
|
| Age Factors | 1 | 2009 | 1860 | 0.060 |
Why?
|
| Guinea Pigs | 2 | 2016 | 124 | 0.060 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2004 | 57 | 0.060 |
Why?
|
| Half-Life | 1 | 2004 | 96 | 0.060 |
Why?
|
| Adrenergic beta-3 Receptor Antagonists | 1 | 2003 | 1 | 0.060 |
Why?
|
| Biological Availability | 1 | 2004 | 79 | 0.060 |
Why?
|
| Benzofurans | 1 | 2003 | 21 | 0.060 |
Why?
|
| Duloxetine Hydrochloride | 1 | 2003 | 9 | 0.060 |
Why?
|
| Drug Evaluation | 1 | 2003 | 47 | 0.060 |
Why?
|
| Dosage Forms | 1 | 2003 | 20 | 0.060 |
Why?
|
| Administration, Cutaneous | 1 | 2003 | 56 | 0.060 |
Why?
|
| Botulinum Toxins | 1 | 2003 | 18 | 0.060 |
Why?
|
| Urography | 1 | 2003 | 21 | 0.060 |
Why?
|
| Hernia | 2 | 2000 | 13 | 0.060 |
Why?
|
| Pyrrolidines | 1 | 2003 | 45 | 0.060 |
Why?
|
| Drug Compounding | 1 | 2003 | 34 | 0.060 |
Why?
|
| Tissue Distribution | 1 | 2004 | 282 | 0.060 |
Why?
|
| Growth Inhibitors | 1 | 2003 | 33 | 0.060 |
Why?
|
| Priapism | 1 | 2003 | 4 | 0.060 |
Why?
|
| Thiophenes | 1 | 2003 | 76 | 0.060 |
Why?
|
| Urinary Calculi | 1 | 2003 | 4 | 0.060 |
Why?
|
| Granulation Tissue | 1 | 2003 | 6 | 0.060 |
Why?
|
| Injections | 3 | 2010 | 119 | 0.060 |
Why?
|
| Erectile Dysfunction | 1 | 2003 | 22 | 0.060 |
Why?
|
| Infertility | 1 | 2003 | 26 | 0.060 |
Why?
|
| Adolescent | 3 | 2011 | 8903 | 0.060 |
Why?
|
| Epidermal Growth Factor | 1 | 2003 | 95 | 0.060 |
Why?
|
| Urothelium | 2 | 2016 | 22 | 0.060 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 2 | 2012 | 18 | 0.060 |
Why?
|
| Ultrasonography | 3 | 2000 | 453 | 0.060 |
Why?
|
| Apamin | 2 | 2012 | 13 | 0.060 |
Why?
|
| Phosphodiesterase Inhibitors | 2 | 2012 | 28 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2005 | 1753 | 0.050 |
Why?
|
| Young Adult | 5 | 2012 | 5708 | 0.050 |
Why?
|
| Terminology as Topic | 1 | 2003 | 141 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2021 | 2323 | 0.050 |
Why?
|
| Transplantation, Homologous | 1 | 2003 | 242 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2005 | 1054 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2017 | 2688 | 0.050 |
Why?
|
| Martial Arts | 1 | 2001 | 4 | 0.050 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2003 | 148 | 0.050 |
Why?
|
| Rectocele | 1 | 2000 | 2 | 0.050 |
Why?
|
| Amitriptyline | 1 | 2000 | 11 | 0.050 |
Why?
|
| Renal Veins | 1 | 2001 | 18 | 0.050 |
Why?
|
| Thigh | 1 | 2001 | 27 | 0.050 |
Why?
|
| Food, Formulated | 1 | 2000 | 11 | 0.050 |
Why?
|
| Urethral Obstruction | 1 | 2001 | 8 | 0.050 |
Why?
|
| Ureteral Obstruction | 1 | 2001 | 25 | 0.050 |
Why?
|
| Phenazopyridine | 1 | 2000 | 5 | 0.050 |
Why?
|
| Ileocecal Valve | 1 | 2000 | 3 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 848 | 0.050 |
Why?
|
| Animals | 5 | 2017 | 20877 | 0.050 |
Why?
|
| Risk Factors | 1 | 2010 | 5719 | 0.050 |
Why?
|
| Abdominal Injuries | 1 | 2001 | 60 | 0.050 |
Why?
|
| Herniorrhaphy | 1 | 2000 | 38 | 0.050 |
Why?
|
| Colonic Polyps | 1 | 2000 | 63 | 0.050 |
Why?
|
| Urinary Sphincter, Artificial | 1 | 2000 | 6 | 0.050 |
Why?
|
| Graft Survival | 1 | 2003 | 465 | 0.050 |
Why?
|
| Orchiectomy | 1 | 1999 | 25 | 0.050 |
Why?
|
| Heparin | 1 | 2000 | 205 | 0.050 |
Why?
|
| Gadolinium DTPA | 1 | 2000 | 48 | 0.040 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2001 | 131 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2016 | 1174 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2001 | 124 | 0.040 |
Why?
|
| Exercise Therapy | 1 | 2021 | 183 | 0.040 |
Why?
|
| Visceral Afferents | 1 | 2019 | 1 | 0.040 |
Why?
|
| Biopsy | 2 | 2000 | 539 | 0.040 |
Why?
|
| Image Enhancement | 1 | 2000 | 143 | 0.040 |
Why?
|
| Sacrum | 1 | 2018 | 14 | 0.040 |
Why?
|
| Vaginal Fistula | 1 | 1998 | 3 | 0.040 |
Why?
|
| Canada | 1 | 2019 | 266 | 0.040 |
Why?
|
| Incontinence Pads | 1 | 2018 | 1 | 0.040 |
Why?
|
| Hysterectomy | 1 | 1998 | 64 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 1998 | 57 | 0.040 |
Why?
|
| National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2017 | 4 | 0.040 |
Why?
|
| Intestinal Diseases | 1 | 1998 | 25 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2012 | 1663 | 0.040 |
Why?
|
| Women's Health | 1 | 2018 | 148 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 1997 | 63 | 0.040 |
Why?
|
| Education | 1 | 2017 | 83 | 0.040 |
Why?
|
| Rectum | 1 | 1997 | 62 | 0.040 |
Why?
|
| Intraoperative Care | 1 | 1997 | 91 | 0.040 |
Why?
|
| Health Services Needs and Demand | 1 | 2017 | 149 | 0.040 |
Why?
|
| Surgical Procedures, Operative | 1 | 1997 | 124 | 0.040 |
Why?
|
| Isoquinolines | 1 | 2016 | 37 | 0.040 |
Why?
|
| Heparin-binding EGF-like Growth Factor | 2 | 2008 | 17 | 0.030 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2016 | 93 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2016 | 137 | 0.030 |
Why?
|
| Species Specificity | 1 | 2016 | 302 | 0.030 |
Why?
|
| Periodicals as Topic | 1 | 1998 | 158 | 0.030 |
Why?
|
| Achievement | 1 | 2015 | 22 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2016 | 337 | 0.030 |
Why?
|
| Child | 1 | 2006 | 6400 | 0.030 |
Why?
|
| Prostate | 1 | 1996 | 116 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2008 | 146 | 0.030 |
Why?
|
| Goals | 1 | 2015 | 65 | 0.030 |
Why?
|
| Cholinergic Agonists | 1 | 2014 | 5 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 333 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 710 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2017 | 310 | 0.030 |
Why?
|
| Purinergic Agonists | 1 | 2013 | 1 | 0.030 |
Why?
|
| Purinergic Antagonists | 1 | 2013 | 1 | 0.030 |
Why?
|
| Suramin | 1 | 2013 | 9 | 0.030 |
Why?
|
| Atropine | 1 | 2013 | 29 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 954 | 0.030 |
Why?
|
| Myography | 1 | 2012 | 4 | 0.030 |
Why?
|
| Diagnostic Techniques, Urological | 1 | 2012 | 3 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 1996 | 475 | 0.030 |
Why?
|
| Muscle Relaxation | 1 | 2012 | 31 | 0.030 |
Why?
|
| Potassium | 1 | 2013 | 168 | 0.030 |
Why?
|
| Spider Venoms | 1 | 2012 | 5 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2013 | 314 | 0.030 |
Why?
|
| Cyclic AMP | 1 | 2012 | 223 | 0.030 |
Why?
|
| Indoles | 1 | 2012 | 146 | 0.030 |
Why?
|
| Toxins, Biological | 1 | 2011 | 23 | 0.030 |
Why?
|
| Isoenzymes | 1 | 2012 | 308 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2012 | 282 | 0.020 |
Why?
|
| Protein Subunits | 1 | 2011 | 99 | 0.020 |
Why?
|
| Benzimidazoles | 1 | 2012 | 128 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 492 | 0.020 |
Why?
|
| Dimethylpolysiloxanes | 1 | 2010 | 7 | 0.020 |
Why?
|
| Zirconium | 1 | 2010 | 9 | 0.020 |
Why?
|
| Polyvinyls | 1 | 2010 | 24 | 0.020 |
Why?
|
| Durapatite | 1 | 2010 | 33 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2011 | 289 | 0.020 |
Why?
|
| Life Style | 1 | 2012 | 338 | 0.020 |
Why?
|
| Cattle | 1 | 2010 | 475 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2010 | 221 | 0.020 |
Why?
|
| Diet | 1 | 2012 | 513 | 0.020 |
Why?
|
| History, 19th Century | 1 | 2008 | 95 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2008 | 71 | 0.020 |
Why?
|
| Cyclic GMP | 1 | 2008 | 99 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 1046 | 0.020 |
Why?
|
| Rats | 1 | 2016 | 5300 | 0.020 |
Why?
|
| Mast Cells | 1 | 2008 | 113 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2008 | 238 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2008 | 239 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2008 | 330 | 0.020 |
Why?
|
| Internationality | 1 | 2005 | 74 | 0.020 |
Why?
|
| Thymidine | 1 | 2003 | 32 | 0.010 |
Why?
|
| Tritium | 1 | 2003 | 101 | 0.010 |
Why?
|
| Epididymitis | 1 | 2003 | 1 | 0.010 |
Why?
|
| Retroperitoneal Fibrosis | 1 | 2003 | 5 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2003 | 138 | 0.010 |
Why?
|
| South Carolina | 1 | 2008 | 2750 | 0.010 |
Why?
|
| Urinary Reservoirs, Continent | 1 | 2000 | 5 | 0.010 |
Why?
|
| Colon, Sigmoid | 1 | 2000 | 13 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 1465 | 0.010 |
Why?
|
| Athletic Injuries | 1 | 2001 | 73 | 0.010 |
Why?
|
| Brachytherapy | 1 | 2000 | 79 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2000 | 193 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2000 | 444 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 1139 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2000 | 2453 | 0.010 |
Why?
|